This provider averages 134 services per working day
Based on 133.7K total services over 4 years (250 working days/year). Learn about impossible service volumes →
This provider's $5.6M in total Medicare payments ranks in the 99th percentile of Nurse Practitioner providers nationally.
Averaging 134 services per working day raises questions about billing patterns.
Medicare payments to this provider grew 1147746% from 2020 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 206137% in 2021
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2020 | $52.50 | $10.41 | 5.04x | $42.09 | $322.69 | 31 | 1 |
| 2021 | $468.54 | $120.67 | 3.88x | $347.87 | $665.5K | 5.5K | 6 |
| 2022 | $231.71 | $59.54 | 3.89x | $172.17 | $1.2M | 20.0K | 12 |
| 2023 | $143.00 | $34.26 | 4.17x | $108.74 | $3.7M | 108.1K | 13 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| J3245 | Injection, tildrakizumab, 1 mg | 21.8K | $2.4M | $109.33 | 3.66x |
| J9332 | Injection, efgartigimod alfa-fcab, 2mg | 31.0K | $772.2K | $24.91 | 4.85x |
| J0517 | Injection, benralizumab, 1 mg | 4.8K | $636.0K | $133.33 | 3.84x |
| J3357 | Ustekinumab, for subcutaneous injection, 1 mg | 3.1K | $425.2K | $138.95 | 4.11x |
| J2350 | Injection, ocrelizumab, 1 mg | 7.2K | $340.8K | $47.33 | 3.43x |
| J1306 | Injection, inclisiran, 1 mg | 32.4K | $304.5K | $9.41 | 6.40x |
| J2182 | Injection, mepolizumab, 1 mg | 11.6K | $267.5K | $23.06 | 3.82x |
| J2356 | Injection, tezepelumab-ekko, 1 mg | 10.5K | $150.4K | $14.32 | 4.80x |
| J2357 | Injection, omalizumab, 5 mg | 4.2K | $126.6K | $30.37 | 3.74x |
| J0897 | Injection, denosumab, 1 mg | 4.0K | $70.1K | $17.43 | 3.46x |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1.2K | $32.4K | $26.17 | 5.96x |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | 231 | $22.2K | $95.97 | 4.90x |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 299 | $14.6K | $48.85 | 4.87x |
| 96372 | Injection of drug or substance under skin or into muscle | 1.2K | $12.3K | $10.11 | 5.19x |
| 96415 | Administration of chemotherapy into vein, each additional hour | 115 | $2.4K | $21.23 | 4.65x |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 35 | $747.86 | $21.37 | 4.73x |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 56 | $245.97 | $4.39 | 4.12x |
This provider submits charges 4.08 times higher than what Medicare actually pays.
A markup ratio of 4.08x means for every $100 Medicare pays, this provider initially charges $408. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data